ADMA Biologics Statement on Tariffs
ADMA Biologics (Nasdaq: ADMA) has issued a statement emphasizing its strategic advantage as a fully U.S.-based biopharmaceutical company amid recent tariff implementations. The company confirms that the new tariffs on foreign goods, services, and manufacturing will have no impact on its operations due to its entirely domestic supply chain and manufacturing infrastructure.
The company's President and CEO, Adam Grossman, highlighted that all manufacturing operations, end-market sales, and customer engagements are conducted exclusively within the United States. ADMA's vertically integrated supply chain, entirely based in the U.S., provides complete domestic control over sourcing, manufacturing, and distribution, aligning with increasing federal and private sector preferences for U.S.-made products.
ADMA Biologics (Nasdaq: ADMA) ha rilasciato una dichiarazione sottolineando il suo vantaggio strategico come azienda biopharmaceutica completamente basata negli Stati Uniti, in seguito alle recenti implementazioni di dazi. L'azienda conferma che i nuovi dazi su beni, servizi e produzioni estere non avranno alcun impatto sulle sue operazioni grazie alla sua catena di approvvigionamento e infrastruttura di produzione completamente domestiche.
Il Presidente e CEO dell'azienda, Adam Grossman, ha evidenziato che tutte le operazioni di produzione, le vendite finali e i rapporti con i clienti si svolgono esclusivamente all'interno degli Stati Uniti. La catena di approvvigionamento verticalmente integrata di ADMA, interamente basata negli Stati Uniti, fornisce un controllo totale domestico su approvvigionamento, produzione e distribuzione, allineandosi con le crescenti preferenze del governo federale e del settore privato per i prodotti realizzati negli Stati Uniti.
ADMA Biologics (Nasdaq: ADMA) ha emitido un comunicado enfatizando su ventaja estratégica como una compañía biofarmacéutica completamente basada en EE. UU. en medio de la reciente implementación de aranceles. La empresa confirma que los nuevos aranceles sobre bienes, servicios y manufactura extranjeros no tendrán impacto en sus operaciones debido a su cadena de suministro y su infraestructura de manufactura completamente nacionales.
El Presidente y CEO de la compañía, Adam Grossman, destacó que todas las operaciones de manufactura, ventas al mercado final y compromisos con los clientes se realizan exclusivamente dentro de los Estados Unidos. La cadena de suministro verticalmente integrada de ADMA, completamente basada en EE. UU., proporciona un control total sobre la adquisición, manufactura y distribución, alineándose con las crecientes preferencias del gobierno federal y del sector privado por productos fabricados en EE. UU.
ADMA Biologics (Nasdaq: ADMA)는 최근 관세 시행에 따라 미국에 본사를 둔 제약회사로서의 전략적 이점을 강조하는 성명을 발표했습니다. 이 회사는 외국 상품, 서비스 및 제조에 대한 새로운 관세가 전적으로 국내 공급망과 제조 인프라 덕분에 운영에 영향을 미치지 않을 것이라고 확인했습니다.
회사의 회장 겸 CEO인 아담 그로스먼은 모든 제조 운영, 최종 시장 판매 및 고객 참여가 미국 내에서 독점적으로 이루어진다고 강조했습니다. ADMA의 수직적으로 통합된 공급망은 미국에 완전히 기반을 두고 있어 조달, 제조 및 유통에 대한 완전한 국내 통제를 제공하며, 미국산 제품에 대한 연방 정부와 민간 부문의 선호가 증가하고 있습니다.
ADMA Biologics (Nasdaq: ADMA) a publié une déclaration soulignant son avantage stratégique en tant qu'entreprise biopharmaceutique entièrement basée aux États-Unis, au milieu des récentes mises en œuvre de droits de douane. L'entreprise confirme que les nouveaux droits de douane sur les biens, services et fabrications étrangers n'auront aucun impact sur ses opérations grâce à sa chaîne d'approvisionnement et à son infrastructure de fabrication entièrement domestiques.
Le président et PDG de l'entreprise, Adam Grossman, a souligné que toutes les opérations de fabrication, les ventes sur le marché final et les engagements clients se déroulent exclusivement aux États-Unis. La chaîne d'approvisionnement intégrée verticalement d'ADMA, entièrement basée aux États-Unis, offre un contrôle total sur l'approvisionnement, la fabrication et la distribution, en accord avec les préférences croissantes du gouvernement fédéral et du secteur privé pour les produits fabriqués aux États-Unis.
ADMA Biologics (Nasdaq: ADMA) hat eine Erklärung abgegeben, in der sie ihren strategischen Vorteil als vollständig in den USA ansässiges biopharmazeutisches Unternehmen inmitten der kürzlichen Einführung von Zöllen betont. Das Unternehmen bestätigt, dass die neuen Zölle auf ausländische Waren, Dienstleistungen und Fertigung keine Auswirkungen auf seine Betriebsabläufe haben werden, da es über eine vollständig inländische Lieferkette und Fertigungsinfrastruktur verfügt.
Der Präsident und CEO des Unternehmens, Adam Grossman, hob hervor, dass alle Fertigungsoperationen, Endmarktverkäufe und Kundenkontakte ausschließlich in den Vereinigten Staaten stattfinden. Die vertikal integrierte Lieferkette von ADMA, die vollständig in den USA basiert, bietet eine vollständige Kontrolle über Beschaffung, Fertigung und Vertrieb im Inland, was mit den zunehmenden Präferenzen des Bundes und des Privatsektors für in den USA hergestellte Produkte übereinstimmt.
- Complete immunity to foreign tariffs due to U.S.-based operations
- Vertically integrated domestic supply chain reduces operational risks
- Strategic alignment with federal and private sector preferences for U.S.-made products
- international market presence and growth opportunities
- Geographic concentration risk in single market
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain
RAMSEY, N.J. and BOCA RATON, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today provided a statement on the recent tariffs put in place and reiterated ADMA’s strategic advantage through fully U.S.-based manufacturing operations, commercialization and end-market sales, and a vertically integrated U.S.-based supply chain.
“ADMA is a U.S.-based company with all manufacturing operations, end-market sales, and customer engagements conducted exclusively within the United States,” said Adam Grossman, President and Chief Executive Officer of ADMA. “The tariffs that have been implemented on foreign goods, services and manufacturing should have no impact on ADMA and its supply chain or production operations. The Company’s vertically integrated supply chain is fully domiciled in the U.S., providing end-to-end domestic control over sourcing, manufacturing, and distribution. Our strategic infrastructure not only ensures enhanced supply chain robustness, resilience and regulatory compliance, but also aligns with increasing federal and private sector preferences for U.S.-made products and services. By maintaining complete operational control within the U.S., ADMA is uniquely well-positioned to capitalize on national economic incentives and deliver reliable, secure, and high-quality offerings to its domestic customer base.”
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,” “our” or the “Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as “confident,” “estimate,” “project,” “intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will,” “is likely,” “will likely,” “position us,” “should,” “could,” “would,” “may,” “potential,” “opportunity” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about the impact of tariffs on the Company and its supply chain or production operations. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
FAQ
How will the new tariffs affect ADMA Biologics operations?
Where are ADMA Biologics' manufacturing facilities located?
What competitive advantage does ADMA have regarding its supply chain?
How does ADMA's U.S.-based strategy align with market preferences?
